Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13803960 | 1.00 | GBA1 (0.55) | GBA1SLC6A4SLC6A2SLC6A3CCR3 | |
| SCHEMBL13791895 | 1.00 | GBA1 (0.55) | GBA1SLC6A4SLC6A2SLC6A3CCR3 | |
| SCHEMBL12076803 | 1.00 | GBA1 (0.55) | GBA1SLC6A4SLC6A2SLC6A3CCR3 | |
| SCHEMBL13803916 | 1.00 | GBA1 (0.55) | GBA1SLC6A4SLC6A2SLC6A3CCR3 | |
| SCHEMBL5456466 | 0.81 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5456472 | 0.81 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6942011 | 0.81 | KCNH2 (0.51) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7001856 | 0.81 | SLC6A2 (0.46) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL13236886 | 0.80 | GBA1 (0.44) | GBA1CCR3 | |
| Hydrochloric Acid SCHEMBL3884383 | 0.79 | CHRM1 (0.45) | SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535597-B2 | Photoreactive ligands and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| US-20200071277-A1 | PHOTOREACTIVE LIGANDS AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2020-03-05 | — | — | US | disclosed |
| EP-2500345-B1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2015-01-28 | — | — | EP | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| EP-2500345-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | disclosed |
| WO-2006130426-A2 | MODULATORS OF CCR-5 ACTIVITY | KEMIA, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | disclosed |
| EP-1244450-A4 | 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | disclosed |
| EP-1244450-A1 | 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6432976-B1 | ANALGESICS; SIDE EFFECT REDUCTION | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| WO-2001032179-A1 | 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535597-B2 | Photoreactive ligands and uses thereof | CLTB, CRYAB, CRYAA | GBA1 3559/4885SLC6A4 3207/4885SLC6A2 3968/4885 |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | GBA1 4362/4885SLC6A4 570/4885SLC6A2 823/4885 |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | HDAC10, HDAC11, HDAC1 | GBA1 308/4885SLC6A4 3419/4885SLC6A2 2458/4885 |
| US-20200071277-A1 | PHOTOREACTIVE LIGANDS AND USES THEREOF | CLTB, CRYAB, CRYAA | GBA1 3559/4885SLC6A4 3207/4885SLC6A2 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.